EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

From Signal to Certainty: Why COPD Needs More Than One Trial

Mario Cazzola, Daiana Stolz, Don D Sin, Maria Gabriella Matera, Paola Rogliani

Lung · 31.07.2026 · 204 (1)

DOI: 10.1007/s00408-026-00914-x ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Lung, online erschienen am 31.07.2026. Verfasst von Mario Cazzola und 4 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy. mario.cazzola@uniroma2.it. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Randomized Controlled Trials as Topic, Drug Approval, Research Design. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Roma Tor Vergata.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The U.S. Food and Drug Administration’s proposal to adopt a single randomized controlled trial (RCT) as the default evidentiary standard for drug approval marks a substantial change in regulatory philosophy. Although advances in mechanistic science, biomarkers, and statistical methods may justify this approach for conditions with significant, biologically coherent treatment effects, applying it to chronic obstructive pulmonary disease (COPD) raises substantial concerns. COPD is a heterogeneous, multifactorial syndrome with variable disease trajectories, modest treatment effects, and limited validated biomarkers. In this context, reliance on a single trial increases inferential fragility, risks type I error, and limits generalizability due to restrictive eligibility criteria and contextual variability. Although biomarker- and trait-based strategies are promising, they remain insufficiently validated to ensure robust estimation of treatment effects across populations. Similarly, the modest effect sizes and endpoint variability in COPD trials amplify the risk of false-positive or context-specific findings. Replication across independent studies primarily serves to test the consistency and robustness of observed effects under varying conditions, rather than to increase statistical power. We discuss a conceptual regulatory framework in which a single RCT may be acceptable only if it meets strict criteria, including large effect sizes, strong biological plausibility, a low risk of bias, and consistent subgroup effects. However, for highly heterogeneous conditions such as COPD, at least two independent studies remain preferable. Alternatively, if a single robust RCT is conducted, equivalent post-marketing validation is required. Ultimately, regulatory standards should be calibrated to biological and methodological uncertainty, balancing timely patient access with evidentiary reliability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveRandomized Controlled Trials as TopicDrug ApprovalResearch DesignHumansUnited StatesBiomarkersUnited States Food and Drug Administration

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy. mario.cazzola@uniroma2.it.
  • Department of Pneumology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
  • Centre for Heart Lung Innovation, Columbia Division of Respiratory Medicine, St. Paul's Hospital, University of British, Vancouver, BC, Canada.
  • Unit of Pharmacology, Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy.
  • Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy.

Förderung

  • Università degli Studi di Roma Tor Vergata

Zitieren

APA

Cazzola, M., Stolz, D., Sin, D. D., Matera, M. G., & Rogliani, P. (2026). From Signal to Certainty: Why COPD Needs More Than One Trial. Lung, 204(1). https://doi.org/10.1007/s00408-026-00914-x

Vancouver

Cazzola M, Stolz D, Sin DD, Matera MG, Rogliani P. From Signal to Certainty: Why COPD Needs More Than One Trial. Lung. 2026;204(1). doi:10.1007/s00408-026-00914-x

BibTeX
@article{Cazzola2026,
  author = {Cazzola, Mario and Stolz, Daiana and Sin, Don D and Matera, Maria Gabriella and Rogliani, Paola},
  title = {From Signal to Certainty: Why COPD Needs More Than One Trial},
  journal = {Lung},
  year = {2026},
  volume = {204},
  number = {1},
  doi = {10.1007/s00408-026-00914-x}
}
Kostenlos starten →